Recite me link

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab with chemotherapy
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Docetaxel monotherapy or combination with Carboplatin/Cisplatin
l. Durvalumab
m. Erlotinib
n. Gefitinib
o. Gemcitabine
p. Lorlatinib
q. Nintedanib with Docetaxel
r. Nivolumab
s. Osimertinib
t. Paclitaxel
u. Pembrolizumab monotherapy
v. Pembrolizumab with chemotherapy
w. Pemetrexed with Carboplatin/Cisplatin
x. Vinorelbine with Carboplatin/Cisplatin
y. Any other active systemic anti-cancer therapy (SACT)
z. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Gemcitabine
e. Nivolumab
f. Osimertinib
g. Paclitaxel
h. Pembrolizumab (Keytruda) Mono
i. Pembrolizumab (Keytruda) with Chemotherapy
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only
Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

Download response Non-small cell lung cancer (NSCLC). 041121.docx